This CME-accredited activity, Gynecologic Oncology at Best of ASCO, is designed to improve the care of gynecologic cancer patients by educating clinicians involved in cancer care. This activity is designed to provide physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals with the latest updates in the field. It will highlight a multidisciplinary approach and the integration of new advances in patient-centered care of breast cancer.
Course Accreditations
Course Summary
| Events Starts | Events Ends |
|---|---|
| 7/18/2025 | 12/31/2025 |
Faculty
Andrea Wahner Hendrickson (MD )
Dr. Andrea E. Wahner Hendrickson, M.D., is a consultant and chair of the Gynecologic Tumor Group in the Division of Medical Oncology, Department of Oncology at Mayo Clinic in Rochester, Minnesota, with a joint appointment in the Department of Internal Medicine. She serves as the interim director of the Early Phase Therapeutics Novel Agents Disease Team for the Mayo Clinic Cancer Center and holds the academic rank of associate professor of oncology and assistant professor of pharmacology, Mayo Clinic College of Medicine and Science. Dr. Wahner Hendrickson earned her medical degree from the University of Minnesota Medical School, followed by an internal medicine residency at the Mayo Clinic College of Medicine. She then completed both a clinical investigator residency and an advanced fellowship in hematology and oncology at the Mayo Clinic. Dr. Wahner Hendrickson is board certified in internal medicine, hematology, and medical oncology. Dr. Wahner Hendrickson’s clinical and research efforts are focused on caring for women with gynecologic malignancies and developing early-phase clinical trials. As a National Cancer Institute (NCI) Ovarian Cancer Task Force member, she reviews and prioritizes national and international clinical trials for ovarian cancer. With an overarching goal of identifying better therapies for ovarian cancer, she has a strong clinical trial record, including leading NCI-sponsored trials and national phase I/II trials within the Experimental Therapeutics Clinical Trials Network and the Mayo Clinic Ovarian Cancer SPORE.
Disclosure
Yes, I have had a financial relationship with an ineligible company within the past 24 months. Financial relationships: Attribution: Self Type of financial relationship: Other Ineligible company: Oxcia Topic: Scientific Advisory Board Attribution: Self Type of financial relationship: Other Ineligible company: Prolynx Topic: Support for clinical trial Attribution: Self Type of financial relationship: Other Ineligible company: TORL biotherapeutics Topic: Support for clinical trial
- Medical oncologists
- Radiation oncologists
- Surgical oncologists
- Oncology residents/fellows
- Oncology NPs/PAs
- Oncology pharmacists
- Oncology nurses
Target Audience
- Discuss new and updated treatment options for patients with gynecologic cancer
- Identify side effects, indications, and contra-indications of therapies used to diagnose and treat gynecologic malignancies.
Learning Objectives
Upon successful completion of this educational activity, participants will be able to: